{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:52:23Z","timestamp":1792795943756,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001254","name":"Ipsen Ltd UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102792","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:38:00Z","timestamp":1719430680000},"page":"102792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review"],"prefix":"10.1016","volume":"129","author":[{"given":"Janet","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Charnley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ogareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102792_b0005","unstructured":"Surveillance, epidemiology, and end results program cancer stat facts: kidney and renal pelvis cancer. <https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html> [accessed January 10, 2023]."},{"key":"10.1016\/j.ctrv.2024.102792_b0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2024.102792_b0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.10.023","article-title":"Prognosis of renal cell carcinoma with bone metastases: experience from a large cancer centre","volume":"107","author":"Ruatta","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2024.102792_b0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102792_b0040","doi-asserted-by":"crossref","first-page":"e83026","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2024.102792_b0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11523-021-00832-3","article-title":"A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab","volume":"16","author":"Desai","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amsu.2018.01.002","article-title":"Skeletal metastasis in renal cell carcinoma: a review","volume":"27","author":"Umer","year":"2018","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.ctrv.2024.102792_b0055","article-title":"Bone metastasis from renal cell carcinoma","volume":"17","author":"Chen","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102792_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100315","article-title":"c-Met expression in renal cell carcinoma with bone metastases","volume":"25","author":"Silva Paiva","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s13577-014-0101-3","article-title":"Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis","volume":"28","author":"Mukai","year":"2015","journal-title":"Hum Cell"},{"key":"10.1016\/j.ctrv.2024.102792_b0070","unstructured":"Brown J, Charnley N, Jones R, Santini D, Ogareva A, Chisholm A. Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: a systematic review. <https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=355436> [accessed August 2023]."},{"key":"10.1016\/j.ctrv.2024.102792_b0075","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2024.102792_b0080","unstructured":"BMJ Best Practice. What is GRADE? <https:\/\/bestpractice.bmj.com\/info\/toolkit\/learn-ebm\/what-is-grade\/> [accessed October 31, 2022]."},{"key":"10.1016\/j.ctrv.2024.102792_b0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2024.102792_b0090","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2021.08.056","article-title":"Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update (abstract 660P)","volume":"32","author":"Choueiri","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0095","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2021.39.15_suppl.4553","article-title":"Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cellcarcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial (abstract 4553)","volume":"39","author":"Apolo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2022.40.6_suppl.342","article-title":"Efficacy and safety of nivolumab in renal cellcarcinoma patients with BONE metastases: results of the GETUG: AFU 26 nivorenmulticenter phase II study (abstract 342)","volume":"40","author":"Velev","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2022.12.028","article-title":"Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: results of the GETUG-AFU26-NIVOREN multicentre phase II study","volume":"182","author":"Velev","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102792_b0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/sj.bjc.6600768","article-title":"Metastatic renal carcinoma comprehensive prognostic system","volume":"88","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0120","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.urology.2011.05.034","article-title":"A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ","volume":"78","author":"Bex","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2024.102792_b0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.2017.75.2170","article-title":"Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase iii randomized trial","volume":"36","author":"Cella","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/annonc\/mdf105","article-title":"A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population","volume":"13","author":"Clark","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0135","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.19.02394","article-title":"Phase Ib\/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003","volume":"38","author":"Dudek","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0140","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0145","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102792_b0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000430989","article-title":"Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib","volume":"89","author":"Kattan","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2024.102792_b0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","article-title":"Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials","volume":"50","author":"Molina","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0160","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","article-title":"Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie","volume":"13","author":"Negrier","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0170","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11523-017-0487-4","article-title":"Long-term duration of first-line axitinib treatment in advanced renal cell carcinoma","volume":"12","author":"Rini","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0175","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/jjco\/hyp089","article-title":"Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma","volume":"39","author":"Shinohara","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0180","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jjco\/hyw103","article-title":"Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study","volume":"46","author":"Tomita","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102792_b0185","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1634\/theoncologist.2019-0316","article-title":"Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial","volume":"24","author":"George","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102792_b0190","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102792_b0195","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2024.102792_b0200","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1038\/bjc.2013.236","article-title":"Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma","volume":"108","author":"Motzer","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0205","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102792_b0210","doi-asserted-by":"crossref","first-page":"e78881","DOI":"10.1371\/journal.pone.0078881","article-title":"Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2024.102792_b0215","doi-asserted-by":"crossref","first-page":"dju033","DOI":"10.1093\/jnci\/dju033","article-title":"Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib","volume":"106","author":"Graham","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102792_b0220","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bone.2015.08.003","article-title":"Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo","volume":"81","author":"Haider","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2024.102792_b0225","first-page":"2033","article-title":"Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption","volume":"115","author":"Stern","year":"2014","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2024.102792_b0230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/0300891620969817","article-title":"Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma","volume":"107","author":"Ratta","year":"2021","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2024.102792_b0235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102792_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100399","article-title":"All bone metastases are not created equal: revisiting treatment resistance in renal cell carcinoma","volume":"31","author":"Brozovich","year":"2021","journal-title":"J Bone Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T19:59:25Z","timestamp":1723665565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":48,"alternative-id":["S0305737224001208"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102792","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102792"}}